Related Experiment Video

Updated: May 27, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

Botulinum toxin type A: new information about an old medicine

Kevin C Smith

    Skin Therapy Letter
    |November 18, 2011
    PubMed

    More Related Videos

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors14:10

    A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

    Published on: November 14, 2014

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators10:30

    A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

    Published on: December 27, 2013

    Related Concept Videos

    Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

    Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

    Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
    The binding of dantrolene to the RYR1...
    Skeletal Muscle Relaxants: Therapeutic Uses01:31

    Skeletal Muscle Relaxants: Therapeutic Uses

    Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
    Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

    Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

    Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
    Although all competitive neuromuscular blockers are designed...
    Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

    Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

    Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
    Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
    Skeletal Muscle Relaxants: Adverse Effects01:21

    Skeletal Muscle Relaxants: Adverse Effects

    Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
    Unlike...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...